M. Dellborg

Publications270
h-index38
Citations7,309
Highly Influential Citations193
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Moons
  • 618 Publications, 10,515 Citations
  • L. Wallentin
  • 682 Publications, 53,282 Citations
  • J. Herlitz
  • 850 Publications, 28,209 Citations
  • R. Califf
  • 1,762 Publications, 145,627 Citations
  • Publications
  • Influence
Universal definition of myocardial infarction.
Chairpersons: Kristian Thygesen (Denmark)*, Joseph S. Alpert (USA)*, Harvey D. White (New Zealand)* Biomarker Group: Allan S. Jaffe, Coordinator (USA), Fred S. Apple (USA), Marcello Galvani (Italy),… Expand
  • 1,520
  • 51
  • PDF
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety…
Background— After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also… Expand
  • 447
  • 13
Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study.
OBJECTIVES The purpose of this study was to determine long-term outcome in adults with congenitally corrected transposition of the great arteries (CCTGA), with particular emphasis on systemic… Expand
  • 503
  • 11
  • PDF
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events.
AIMS The study evaluated the associations between glycometabolic parameters at admission and during hospitalization and 2 year all-cause mortality risk in an unselected cohort of consecutive patients… Expand
  • 285
  • 10
  • PDF
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.
AIMS We evaluated the relationship of renal function and ischaemic and bleeding risk as well as the efficacy and safety of ticagrelor in stable patients with prior myocardial infarction (MI). … Expand
  • 66
  • 6
  • PDF
Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50
Background— Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for thrombin on human platelets that is also present on vascular endothelium and smooth muscle.… Expand
  • 156
  • 5
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial.
BACKGROUND Patients in clinical trials of fibrinolytic agents have been shown to be younger, less often female, and to have lower risk characteristics and a better outcome compared with unselected… Expand
  • 53
  • 4
Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden
Aims To describe trends in incidence and case fatality among younger (18–54 years) and older (55–84 years) Swedish patients with heart failure (HF). Methods and results Through linking the Swedish… Expand
  • 87
  • 4
  • PDF
Rupture of the myocardium. Occurrence and risk factors.
The occurrence of myocardial rupture was studied in a well defined unselected population of patients with acute myocardial infarction, and the group of patients who died of rupture of the heart were… Expand
  • 121
  • 3
Bundle-branch block in a general male population: the study of men born 1913.
BACKGROUND Interest in bundle-branch block has focused primarily on its role as a predictor of mortality and coexisting cardiovascular diseases. Previous studies of prevalence, correlation to… Expand
  • 223
  • 3
  • PDF